Assistance Publique-Hopitaux De Paris

Université Pierre Et Marie Curie (Paris 6)

Université De Paris

Centre National De La Recherche Scientifique

National Institute of Health and Medical Research

Université Paris Descartes

Sorbonne Université

Université Paris—sud

Institut Gustave Roussy

Centre National De La Recherche Scientifique-Cnrs

Institut National De La Sante Et De La Recherche Medicale (Inserm)

Sorbonne Unicersite

Université Paris-Saclay

Université Pierre Et Marie Curie

Vincent Calvez

Anne-Geneviève Marcelin

Philippe Grange

Nicolas Dupin

Matthieu Sollogoub

Anne-Genevieve Marcelin

Laurent Bouteiller

Joel Raingeaud

Dmitri Colesnic

Adélie Gothland

Julien Rossignol

Joël Raingeaud

Cathia Soulie

Mickaël Menand

Melanie Etheve-Quelquejeu

Pierre Evenou

Laurent Micouin

Aurélie Blond

Anne-Geneviève Marcellin

Mickael Menand

Adelie Gothland

Emilie Corrot

Mélanie Etheve-Quelquejeu

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis. 

Meclozine derivatives and diclazuril derivatives for use in the prevention and/or the treatment of disorders associated to the inflammation induced by

The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.

Capped cyclodextrin-hydrophobic moiety conjugate, cyclodextrin supramolecular polymer, and cyclodextrin-siRNA complex and method of synthesis thereof

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds. 

Hycanthone derivatives and Primaquine derivatives for use in the prevention and/or the treatment of disorders associated to gammaherpesvirus

A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.

Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases

The present invention describes the use of nucleoside analogs for the treatment of viral infections, in particular of an HIV infection, and also compositions comprising at least one of these analogs, and a method for evaluating the sensitivity to said treatment.

Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment

The present invention relates to interfering RNAs, in particular miRNAs, capable of specifically blocking the replication of a strain of the HIV virus that is resistant to an antiretroviral compound, and use thereof for treating infections by this type of virus.

Use of interfering rna for treating an hiv infection

Growing community of inventors

Paris, France

Vincent Calvez